AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.35 Billion USD | -16.12% |
| 2022 | 31.42 Billion USD | 0.53% |
| 2021 | 28.28 Billion USD | 280.67% |
| 2020 | 21.14 Billion USD | -49.64% |
| 2019 | 16.26 Billion USD | 69.31% |
| 2018 | 13.68 Billion USD | -26.55% |
| 2017 | 11.77 Billion USD | 4.92% |
| 2016 | 10.81 Billion USD | 26.27% |
| 2015 | 9.69 Billion USD | 99.5% |
| 2014 | 6.28 Billion USD | -36.03% |
| 2013 | 6.91 Billion USD | -5.83% |
| 2012 | 6.97 Billion USD | 42.39% |
| 2011 | 4.94 Billion USD | -17.08% |
| 2010 | 6.02 Billion USD | 4.83% |
| 2009 | 6.64 Billion USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.55 Billion USD | -16.12% |
| 2024 Q3 | 7.04 Billion USD | -30.8% |
| 2024 Q2 | 7.12 Billion USD | 28.29% |
| 2023 Q2 | 7.2 Billion USD | 24.18% |
| 2023 Q4 | 6.62 Billion USD | 40.72% |
| 2023 FY | - USD | -31.93% |
| 2023 Q1 | 5.79 Billion USD | -29.79% |
| 2023 Q3 | 4.7 Billion USD | -34.62% |
| 2022 Q1 | 6.77 Billion USD | -4.01% |
| 2022 Q3 | 6.8 Billion USD | 235.2% |
| 2022 Q4 | 7.65 Billion USD | 12.5% |
| 2022 FY | - USD | 0.53% |
| 2022 Q2 | 2.03 Billion USD | -70.0% |
| 2021 Q2 | 6.64 Billion USD | 5.11% |
| 2021 Q3 | 6.43 Billion USD | -3.13% |
| 2021 Q4 | 7.05 Billion USD | 9.64% |
| 2021 FY | - USD | 280.67% |
| 2021 Q1 | 6.31 Billion USD | 8.59% |
| 2020 Q3 | 5.54 Billion USD | 140.44% |
| 2020 Q4 | 5.81 Billion USD | 4.89% |
| 2020 FY | - USD | -49.64% |
| 2020 Q2 | 2.3 Billion USD | -44.57% |
| 2020 Q1 | 4.16 Billion USD | -6.79% |
| 2019 FY | - USD | 69.31% |
| 2019 Q1 | 3.51 Billion USD | 275.74% |
| 2019 Q2 | 3.9 Billion USD | 11.07% |
| 2019 Q3 | 3.12 Billion USD | -20.04% |
| 2019 Q4 | 4.46 Billion USD | 43.11% |
| 2018 Q1 | 3.34 Billion USD | 54.79% |
| 2018 FY | - USD | -26.55% |
| 2018 Q4 | -1.99 Billion USD | -155.62% |
| 2018 Q3 | 3.59 Billion USD | 12.14% |
| 2018 Q2 | 3.2 Billion USD | -4.27% |
| 2017 Q1 | 2.79 Billion USD | 3.98% |
| 2017 FY | - USD | 4.92% |
| 2017 Q4 | 2.16 Billion USD | -29.86% |
| 2017 Q2 | 3.05 Billion USD | 9.31% |
| 2017 Q3 | 3.08 Billion USD | 1.02% |
| 2016 Q3 | 2.66 Billion USD | -0.41% |
| 2016 Q4 | 2.68 Billion USD | 0.79% |
| 2016 FY | - USD | 26.27% |
| 2016 Q1 | 2.54 Billion USD | 7.25% |
| 2016 Q2 | 2.67 Billion USD | 5.11% |
| 2015 Q3 | 2.11 Billion USD | 3.43% |
| 2015 FY | - USD | 99.5% |
| 2015 Q4 | 2.37 Billion USD | 12.41% |
| 2015 Q2 | 2.04 Billion USD | 10.68% |
| 2015 Q1 | 1.84 Billion USD | 931.08% |
| 2014 Q2 | 1.71 Billion USD | 10.77% |
| 2014 Q1 | 1.55 Billion USD | -10.66% |
| 2014 FY | - USD | -36.03% |
| 2014 Q4 | -222 Million USD | -115.83% |
| 2014 Q3 | 1.4 Billion USD | -18.35% |
| 2013 Q4 | 1.73 Billion USD | 8.1% |
| 2013 Q3 | 1.6 Billion USD | -4.97% |
| 2013 Q2 | 1.68 Billion USD | 10.25% |
| 2013 Q1 | 1.53 Billion USD | -28.07% |
| 2013 FY | - USD | -5.83% |
| 2012 Q1 | 1.29 Billion USD | -23.86% |
| 2012 FY | - USD | 42.39% |
| 2012 Q2 | 1.71 Billion USD | 32.38% |
| 2012 Q3 | 1.82 Billion USD | 6.16% |
| 2012 Q4 | 2.12 Billion USD | 16.84% |
| 2011 Q1 | 1.13 Billion USD | 0.0% |
| 2011 Q3 | 368.84 Million USD | -78.06% |
| 2011 Q4 | 1.7 Billion USD | 361.9% |
| 2011 Q2 | 1.68 Billion USD | 47.64% |
| 2011 FY | - USD | -17.08% |
| 2010 FY | - USD | 4.83% |
| 2009 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 19.41 Billion USD | -35.747% |
| Bristol-Myers Squibb Company Ce | 19.41 Billion USD | -35.747% |
| Johnson & Johnson | 23.72 Billion USD | -11.098% |
| Eli Lilly and Company | 8.56 Billion USD | -207.64% |
| Merck & Co., Inc. | 6.9 Billion USD | -281.613% |
| Novartis AG | 18.28 Billion USD | -44.143% |
| Organon & Co. | 1.43 Billion USD | -1735.515% |
| Pfizer Inc. | 9.55 Billion USD | -175.798% |